The Rising Fortunes of TG Therapeutics Stock in Light of Multiple Sclerosis Focus

Actionable Trade Ideas

always free


TG Therapeutics IncΒ TGTX revealed preliminary BRIUMVI U.S.Β net product sales for Q4 and FY23.

The expected BRIUMVI U.S. net product revenue for Q4 is around $40 million and $89 million for FY23.

The company anticipates a year-end 2023 cash position of about $215 million.

Prospects: TGTX envisions BRIUMVI U.S. net product revenue of $41 million-$46 million in Q1 and $220 million-$260 million for FY24.

The company aims to achieve operating expenses of approximately $250 million in FY24.

In FY24, TGTX plans to commence clinical development of subcutaneous BRIUMVI and initiate a trial evaluating BRIUMVI in autoimmune diseases beyond Multiple Sclerosis (MS).

Additionally, the company plans to commence a trial for evaluating azer-cel in autoimmune disease and present data from the ENHANCE Phase 3b CD20 switch trial at multiple conferences this year.

Yesterday, TGTX entered into a deal withΒ Precision BioSciences, Inc.Β DTIL to acquire a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseasesΒ and all other non-oncology indications.

As of Q3 FY23, TG Therapeutics’ cash position stood at $229.2 million.

Price Movement: TGTX shares are up 10.52% at $23.22 premarket on the last check Wednesday.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.